Roche/Genentech’s Tecentriq represents the best value for money among the new generation of immunotherapy treatments for lung cancer – but is still overpriced.
The first instalment of two-part article looking at people behind the most important events and trends in pharma, biotech and wider world of healthcare in 2015.
